• 四川大學(xué)華西醫(yī)院肛腸外科(成都610041);

目的 探討在多學(xué)科協(xié)作(multi-disciplinary team, MDT)診治模式下接受新輔助化療聯(lián)合手術(shù)綜合治療的結(jié)直腸癌患者的生存質(zhì)量。方法 應(yīng)用歐洲癌癥研究與治療組織的生存質(zhì)量核心問卷(quality of life questionnaire-core 30,QLQ-C30),對2007年5~8月期間四川大學(xué)華西醫(yī)院普外科肛腸專業(yè)治療組收治確診為結(jié)直腸癌并接受新輔助化療聯(lián)合手術(shù)治療的患者進(jìn)行新輔助化療前、新輔助化療后以及手術(shù)后1個(gè)月生存質(zhì)量的評估并比較。結(jié)果 本研究納入了57例符合條件的患者,其中男34例,女23例; 平均年齡56.33歲; 右半結(jié)腸癌10例,左半結(jié)腸癌4例,直腸癌43例。新輔助化療前的總體健康狀況與新輔助化療后以及手術(shù)后1個(gè)月時(shí)比較略好,其差異有統(tǒng)計(jì)學(xué)意義(P<0.001); 但新輔助化療后與手術(shù)后1個(gè)月間的差異沒有統(tǒng)計(jì)學(xué)意義(P gt;0.05)。功能子量表中,軀體功能、角色功能、認(rèn)知功能和社會功能,在新輔助化療前、新輔助化療后以及手術(shù)后1個(gè)月之間的差異,均沒有統(tǒng)計(jì)學(xué)意義(P gt;0.05); 但手術(shù)后1個(gè)月時(shí)的情緒功能與手術(shù)前的2個(gè)評估點(diǎn)比較則明顯下降(P<0.005),而術(shù)前的2個(gè)評估點(diǎn)間比較差異沒有統(tǒng)計(jì)學(xué)意義(P gt;0.05)。癥狀子量表中,呼吸困難和便秘的癥狀評分,3個(gè)評估點(diǎn)間比較,差異均沒有統(tǒng)計(jì)學(xué)意義(P gt;0.05)。術(shù)后1個(gè)月時(shí)患者疲倦、疼痛、睡眠困難、食欲減退及腹瀉癥狀的程度,與新輔助化療前及新輔助化療后比較均有加重,其差異有統(tǒng)計(jì)學(xué)意義(P<0.01); 但新輔助化療前和新輔助化療后比較,以上5項(xiàng)癥狀評分之間差異沒有統(tǒng)計(jì)學(xué)意義(P gt;0.05)。新輔助化療后的惡心嘔吐癥狀,較新輔助化療前以及手術(shù)后1個(gè)月時(shí)均更嚴(yán)重,其差異有統(tǒng)計(jì)學(xué)意義(P<0.01); 而新輔助化療前和手術(shù)后1個(gè)月之間,該癥狀的評分差異沒有統(tǒng)計(jì)學(xué)意義(P gt;0.05)。經(jīng)濟(jì)困難的程度新輔助化療后比新輔助化療前更嚴(yán)重,手術(shù)后1個(gè)月比新輔助化療后更嚴(yán)重,其差異均有統(tǒng)計(jì)學(xué)意義(P<0.001)。結(jié)論 MDT診治模式下新輔助化療聯(lián)合手術(shù)綜合治療過程中,化療干預(yù)手段會使生存質(zhì)量降低,這可能與其副反應(yīng)相關(guān),但其不良反應(yīng)可能并不會實(shí)際影響到術(shù)后患者的部分主觀感受; 而結(jié)直腸癌外科手術(shù)干預(yù)可能是造成患者術(shù)后近期內(nèi)更多的不適感的主要原因,但并不會額外增加綜合治療后患者的生存質(zhì)量負(fù)擔(dān)。不同綜合治療模式對患者生存質(zhì)量的影響,以及綜合治療的成本-效果是需要進(jìn)一步探討的問題。

引用本文: 汪曉東,劉春娟,陳增蓉,邱萌,李立. 多學(xué)科協(xié)作診治模式下新輔助化療聯(lián)合手術(shù)治療結(jié)直腸癌患者的生存質(zhì)量評估. 中國普外基礎(chǔ)與臨床雜志, 2008, 15(5): 371-374. doi: 復(fù)制

1. 汪曉東, 李亞倫, 邱萌, 等. 多學(xué)科協(xié)作診治模式下新輔助化療對直腸癌手術(shù)的影響 [J]. 中國普外基礎(chǔ)與臨床雜志, 2008; 15(2)∶136.
2. Scarpa M, Erroi F, Ruffolo C, et al. Minimally invasive surgery for colorectal cancer: quality of life, body image, cosmesis, and functional results [J]. Surg Endosc, 2008; Apr, 4 \[Epub ahead of print\].
3. Miguel RS, López-González AM, Sanchez-Iriso E, et al. Measuring health-related quality of life in drug clinical trials: is it given due importance? [J] Pharm World Sci, 2008; 30(2)∶154.
4. 汪曉東, 邱萌, 李亞倫, 等. 多學(xué)科協(xié)作診治模式下結(jié)直腸癌不同周期新輔助化療聯(lián)合手術(shù)的方案研究 [J]. 中國普外基礎(chǔ)與臨床雜志, 2008; 15(3)∶210.
5. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst, 1993; 85(5)∶365.
6. Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) [J]. J Epidemiol, 2004; 14(6)∶193.
7. 汪曉東, 馮碩, 游小林, 等. 結(jié)直腸腫瘤多學(xué)科協(xié)作診治模式下的隨訪體系建設(shè) [J]. 中國普外基礎(chǔ)與臨床雜志, 2007; 14(6)∶709.
8. Schwenk W, Neudecker J, Haase O, et al. Comparison of EORTC quality of life core questionnaire (EORTC-QLQ-C30) and gastrointestinal quality of life index (GIQLI) in patients undergoing elective colorectal cancer resection [J]. Int J Colorectal Dis, 2004; 19(6)∶554.
9. Rotonda C, Conroy T, Mercier M, et al. Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C [J]. Qual Life Res, 2008; 17(3)∶437.
10. Hassan I, Cima RR. Quality of life after rectal resection and multimodality therapy [J]. J Surg Oncol, 2007; 96(8)∶684.
11. Luppi G, Santantonio M, Bertolini F, et al. Preoperative concomitant radiotherapy and chemotherapy in ultrasound-staged T3 and T4 rectal cancer [J]. Tumori, 2003; 89(2)∶152.
  1. 1. 汪曉東, 李亞倫, 邱萌, 等. 多學(xué)科協(xié)作診治模式下新輔助化療對直腸癌手術(shù)的影響 [J]. 中國普外基礎(chǔ)與臨床雜志, 2008; 15(2)∶136.
  2. 2. Scarpa M, Erroi F, Ruffolo C, et al. Minimally invasive surgery for colorectal cancer: quality of life, body image, cosmesis, and functional results [J]. Surg Endosc, 2008; Apr, 4 \[Epub ahead of print\].
  3. 3. Miguel RS, López-González AM, Sanchez-Iriso E, et al. Measuring health-related quality of life in drug clinical trials: is it given due importance? [J] Pharm World Sci, 2008; 30(2)∶154.
  4. 4. 汪曉東, 邱萌, 李亞倫, 等. 多學(xué)科協(xié)作診治模式下結(jié)直腸癌不同周期新輔助化療聯(lián)合手術(shù)的方案研究 [J]. 中國普外基礎(chǔ)與臨床雜志, 2008; 15(3)∶210.
  5. 5. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst, 1993; 85(5)∶365.
  6. 6. Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) [J]. J Epidemiol, 2004; 14(6)∶193.
  7. 7. 汪曉東, 馮碩, 游小林, 等. 結(jié)直腸腫瘤多學(xué)科協(xié)作診治模式下的隨訪體系建設(shè) [J]. 中國普外基礎(chǔ)與臨床雜志, 2007; 14(6)∶709.
  8. 8. Schwenk W, Neudecker J, Haase O, et al. Comparison of EORTC quality of life core questionnaire (EORTC-QLQ-C30) and gastrointestinal quality of life index (GIQLI) in patients undergoing elective colorectal cancer resection [J]. Int J Colorectal Dis, 2004; 19(6)∶554.
  9. 9. Rotonda C, Conroy T, Mercier M, et al. Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C [J]. Qual Life Res, 2008; 17(3)∶437.
  10. 10. Hassan I, Cima RR. Quality of life after rectal resection and multimodality therapy [J]. J Surg Oncol, 2007; 96(8)∶684.
  11. 11. Luppi G, Santantonio M, Bertolini F, et al. Preoperative concomitant radiotherapy and chemotherapy in ultrasound-staged T3 and T4 rectal cancer [J]. Tumori, 2003; 89(2)∶152.